Animerra

Investors · 1

AN

Anterra CapitalreportedAmsterdam · $20M

$6.5M disclosed across 1 round · 2025

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

AN

ANI Pharmaceuticals5 shared keywordsANI Pharmaceuticals is a pharmaceutical company focused on rare disease treatments, developing and marketing therapies such as an intravitreal implant for chronic non-infectious uveitis. It is a publicly traded company serving patients through its rare disease and pharmaceutical product portfolio.

IN

Invenra4 shared keywordsInvenra develops proprietary platform technologies to discover and develop novel bi- and multi-specific antibody therapies, with an initial focus on oncology. The company is advancing pipelines of antibody candidates with partners and intends to expand into additional disease categories.

BI

BIOVECTRA3 shared keywordsBIOVECTRA is a contract development and manufacturing organization (CDMO) with research and development capabilities in biologics process development, complex chemistry, and analytical development. Its work spans recombinant proteins, viral vectors, mRNA vaccines, and pharmaceutical process development for the biotech and pharmaceutical industries.

NE

Neumora Therapeutics3 shared keywordsNeumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.

AZ

Azitra3 shared keywords

Companies competing with Animerra for the same Google search keywords, organic and paid, via search-intersection analysis.